Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals, Inc. (ABOS) is a clinical-stage biopharmaceutical company advancing sabirnetug (ACU193), an investigational monoclonal antibody targeting toxic amyloid-beta oligomers in Alzheimer's disease. This page provides authorized news updates and press releases directly from the company and verified sources.
Key resources for stakeholders include updates on clinical trial progress, regulatory milestones, and strategic partnerships. All content is curated to meet investor needs for timely, accurate information on therapeutic developments and corporate announcements.
Regular updates cover clinical trial results, manufacturing advancements, scientific presentations, and financial disclosures. The news collection serves as a historical record of ABOS's progress in developing novel neurodegenerative disease treatments.
Bookmark this page for streamlined access to essential updates about Acumen's Alzheimer's research program and corporate developments. Check back regularly for new information directly affecting investment analysis and industry monitoring.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced on Nov 17, 2025 that the first participant was dosed in the open-label extension (OLE) of its Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) in people with early Alzheimer’s disease.
The OLE offers participants who completed the 18-month placebo-controlled portion additional dosing of 35 mg/kg IV every four weeks for 52 weeks. Clinical measures and safety monitoring remain the same. The company cited Phase 1 INTERCEPT-AD results showing favorable safety, low ARIA-E rates, target engagement, and biomarker effects including amyloid plaque reduction at highest doses. Acumen expects topline ALTITUDE-AD results in late 2026.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported Q3 2025 results and a business update on Nov. 12, 2025. The company had $136.1 million in cash, cash equivalents and marketable securities as of Sept. 30, 2025, which it expects will support operations into early 2027. Acumen continues its Phase 2 ALTITUDE-AD study of sabirnetug (ACU193) and began dosing the open-label extension in Nov. 2025. The company expects non-clinical data for its Enhanced Brain Delivery program in early 2026 and Phase 2 topline results for ALTITUDE-AD in late 2026. Q3 R&D expense was $22.0M and net loss was $26.5M.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced that George Golumbeski, Ph.D. has been appointed Chairman of its Board of Directors, bringing more than 30 years of biopharma experience.
The Board now totals eight members. Management highlighted Golumbeski’s expertise in portfolio strategy, collaborations, licensing and M&A and said his experience aligns with anticipated catalysts next year for Acumen’s Phase 2 sabirnetug trial and its Enhanced Brain Delivery program.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced it will report third quarter 2025 financial results on Wednesday, November 12, 2025. The company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
Investors must register in advance to receive dial-in numbers and PIN; the live webcast link will be provided and an archived webcast will be available for at least 30 days in the Investors section of the company website.
Acumen Pharmaceuticals (NASDAQ: ABOS) said management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, Nov. 11, 2025 at 4:40 p.m. ET. The company is a clinical-stage biopharmaceutical developer focused on therapeutics targeting toxic soluble amyloid beta oligomers for Alzheimer’s disease. A live webcast will be available via the company Investors page and archived for 90 days.
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, has announced its participation in two upcoming investor conferences in September 2025.
The company will participate in Citi's 2025 Biopharma Back to School Conference with a fireside chat on September 2 at 3:15 p.m. ET, and the Cantor Global Healthcare Conference 2025 with a fireside chat on September 5 at 9:10 a.m. ET. Both presentations will be available via webcast on the company's website for 90 days.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported Q2 2025 financial results and business updates for its Alzheimer's disease therapeutics development. The company maintains a strong cash position of $166.2 million as of June 30, 2025, expected to fund operations into early 2027.
Key developments include operational innovations in the ALTITUDE-AD Phase 2 trial of sabirnetug, achieving 40% reduction in screening costs through innovative biomarker testing. The company also announced a collaboration with JCR Pharmaceuticals to develop Enhanced Brain Delivery (EBD™) therapy, combining sabirnetug with JCR's blood-brain barrier-penetrating technology.
Financial results show R&D expenses increased to $37.1 million from $19.5 million year-over-year, while net loss widened to $41.0 million from $20.5 million. Topline results from ALTITUDE-AD are expected in late 2026.
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, has scheduled its second quarter 2025 financial results announcement for August 12, 2025.
The company will host a conference call and audio webcast at 8:00 a.m. ET to discuss business updates and financial performance. Participants must pre-register at least one day in advance to receive dial-in information. The webcast will be archived for 30 days on Acumen's investor relations website.
Acumen Pharmaceuticals (NASDAQ: ABOS) presented significant findings at the Alzheimer's Association International Conference (AAIC) 2025 regarding their Phase 2 ALTITUDE-AD study of sabirnetug for early Alzheimer's disease. The company reported a 40% reduction in clinical trial screening costs through an innovative pTau217 blood-based screening assay.
The two-step screening process demonstrated high efficiency, with 48% of participants meeting initial pTau217 thresholds and 81% of those subsequently confirming amyloid positivity. Additionally, nonclinical studies revealed sabirnetug's superior selectivity for amyloid beta oligomers (AβOs), achieving 8,750-fold selectivity for Aβ1-42 stabilized oligomers over Aβ1-40 monomers, outperforming other tested antibodies including lecanemab and aducanumab.
Acumen Pharmaceuticals (NASDAQ: ABOS) has entered a strategic collaboration with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer's disease. The partnership combines Acumen's amyloid beta oligomer-selective antibody expertise with JCR's blood-brain barrier penetrating technology (J-Brain Cargo®).
The collaboration follows over a year of feasibility work and aims to develop up to two candidates, with preclinical data expected in early 2026. Acumen's lead program, sabirnetug, has shown promising results in Phase 1 trials and is currently in a Phase 2 ALTITUDE-AD trial with 542 patients, with topline results expected in late 2026.
Under the agreement, JCR will receive an upfront payment, potential option payment, milestone payments, and single-digit percentage royalties on future sales.
FAQ
What is the current stock price of Acumen Pharmaceuticals (ABOS)?
What is the market cap of Acumen Pharmaceuticals (ABOS)?
